Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents

Koichi Kamei(National Center For Child Health and Development), Shuichi Ito(Yokohama City University), Takanori Funaki(National Center For Child Health and Development), Toshinao Kawai(National Center For Child Health and Development), Isao Miyairi(National Center For Child Health and Development), Jun Abe(The University of Texas MD Anderson Cancer Center), Katsuhiro Arai(National Center For Child Health and Development), Masafumi Onodera(National Center For Child Health and Development), Kenji Ishikura(Kitasato University), Kensuke Shoji(National Center For Child Health and Development), Reiko Ito(National Center For Child Health and Development), Masao Ogura(Hokkaido University Hospital)
The Journal of Pediatrics
February 28, 2018
10.1016/j.jpeds.2017.12.061
Cited by 39

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135